Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 6Recruiting 5Terminated 4Withdrawn 2Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 83Metastatic Castration Resistant Prostate Cancer 9Breast Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Prostate Cancer Metastatic 4Castration-resistant Prostate Cancer 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Triple Negative Breast Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Seizures 1Recurrent Endometrial Endometrioid Adenocarcinoma 1Prostate Carcinoma Metastatic to the Bone 1Primary Dysautonomias 1Primary Breast Cancer ER+ve 1Pharmacokinetics of MDV3100 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Non-metastatic, Hormone naïve Prostate Cancer 1Non-metastatic Prostate Cancer 1Metastatic Progressive Castration-resistant Prostate Cancer 1

Interventions

enzalutamide 6radium Ra 223 dichloride 5Docetaxel 2Abiraterone Acetate 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1quemliclustat 1pembrolizumab 1atezolizumab 1apalutamide 1Standard of Care 1Radium-223 1Prednisone 1Nivolumab 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms, Castration-Resistant × enzalutamide × Clear all
NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Pfizer

Completed
2,731 enrolled 14 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT02204072 2025-07-15

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Boehringer Ingelheim

Phase 1 Completed
120 enrolled 28 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05520138 2024-09-27

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Pfizer

Completed
5,506 enrolled 11 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03016312 2024-08-09

IMbassador250

Hoffmann-La Roche

Phase 3 Completed
759 enrolled 22 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03927391 2024-06-12

REDOSE

Radboud University Medical Center

Phase 4 Completed
57 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡